

Patient ID SA00100568	Patient Name TESTINGRNV, REPORT	Birth Date 1999-11-11	Gender M	Age 17
Order Number SA00100568	Client Order Number SA00100568	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 08 Nov 2017 06:00		

PV (JAK2 V617F, Exon 12-15) Reflex

PV Reflex Result

see interpretation

MCR

sequencing of JAK2, exons 12–15 (see Mayo Medical Laboratories Interpretive Handbook for method details). The sensitivity of this assay is approximately 20%, such that samples containing lower percentages of mutated nucleic acid will appear negative.

Specimen Type

Peripheral blood

MCR

Comments:

Negative test results do not exclude the possibility of a myeloproliferative neoplasm (MPN), although the likelihood of involvement by polycythemia vera is low in this sample. Of note, samples containing percentages of mutated nucleic acid below the analytic sensitivity stated above may not be identified. If clinical suspicion is high for primary myelofibrosis (PMF) or essential thrombocythemia (ET), consider additional testing for CALR with reflex to MPL (test ID: MPNCM). Clinicopathologic correlation is recommended for a definitive diagnosis. If there is a history of life-long or familial erythrocytosis, evaluation for a hereditary cause may be considered. If desired, please order an erythrocytosis evaluation (REVE). The REVE evaluation assays for high oxygen affinity hemoglobin variants, EPOR, BPGM and other oxygen sensing pathway mutations. Additional sample required.

Final Diagnosis

① MCR

Peripheral blood, JAK2 V617F mutation analysis:

Negative for JAK2 V617F.

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.06% (see Mayo Medical Laboratories Interpretive Handbook for method details).

Peripheral blood, JAK2 exons 12–15 mutation analysis:

Negative. No mutation was detected in JAK2, exons 12–15.

Method summary - JAK2 exons 12–15 mutation analysis: Total RNA was extracted and converted to cDNA, followed by Sanger

Signing Pathologist: Melissa Tricker-Klar

Received: 08 Nov 2017 16:16

Reported: 08 Nov 2017 17:25

Laboratory Notes

- ① This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292